Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology.
Serif Biomedicines has raised $50.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Serif Biomedicines's investors include Flagship Pioneering.
Serif Biomedicines is headquartered in Cambridge, United States.
Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology.
Serif Biomedicines is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Serif Biomedicines — Funding & Investors." VCBacked, April 21, 2026, https://www.vcbacked.co/company/serif-biomedicines. Accessed October 11, 2026.
VCBacked. (2026). Serif Biomedicines — Funding & Investors. Retrieved October 11, 2026, from https://www.vcbacked.co/company/serif-biomedicines
{{cite web |title=Serif Biomedicines — Funding & Investors |url=https://www.vcbacked.co/company/serif-biomedicines |website=VCBacked |access-date=October 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated